Citius Oncology (CTOR) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Maxim Group | Upgraded | Hold → Buy | $6.00 | Sep 23, 2025 |
| Maxim Group | Downgraded | Buy → Hold | — | May 23, 2025 |
| Maxim Group | Initiated Coverage | Buy | $3.00 | Nov 27, 2024 |
| EF Hutton | Maintained | Buy | $6.00 | Aug 13, 2024 |
Frequently asked questions
Is CTOR a buy, sell, or hold?
Analysts covering Citius Oncology currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CTOR?
On Sep 23, 2025, Maxim Group upgraded Citius Oncology to Buy with a price target of $6.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.